Skip to Content

Generic Rhopressa Availability

Last updated on Aug 11, 2021.

Rhopressa is a brand name of netarsudil ophthalmic, approved by the FDA in the following formulation(s):

RHOPRESSA (netarsudil mesylate - solution/drops;ophthalmic)

  • Manufacturer: AERIE PHARMS INC
    Approval date: December 18, 2017
    Strength(s): EQ 0.02% BASE [RLD]

Has a generic version of Rhopressa been approved?

No. There is currently no therapeutically equivalent version of Rhopressa available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Rhopressa. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Dual mechanism inhibitors for the treatment of disease
    Patent 10,174,017
    Issued: January 8, 2019
    Assignee(s): Aerie Pharmaceuticals, Inc.

    Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

    Patent expiration dates:

    • January 27, 2030
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 10,532,993

    Patent expiration dates:

    • July 11, 2026
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  • Patent 10,588,901

    Patent expiration dates:

    • March 14, 2034
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 10,654,844

    Patent expiration dates:

    • January 27, 2030
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 10,882,840

    Patent expiration dates:

    • July 11, 2026
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  • Patent 11,021,456

    Patent expiration dates:

    • July 11, 2026
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  • Patent 11,028,081

    Patent expiration dates:

    • January 27, 2030
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
  • Dual mechanism inhibitors for the treatment of disease
    Patent 8,394,826
    Issued: March 12, 2013
    Assignee(s): Aerie Pharmaceuticals, Inc.

    Provided are compounds that are inhibitors of both rho kinase and of a monoamine transporter (MAT) act to improve the disease state or condition. Further provided are compositions comprising the compounds. Further provided are methods for treating diseases or conditions, the methods comprising administering compounds according to the invention. One such disease may be glaucoma for which, among other beneficial effects, a marked reduction in intraocular pressure (IOP) may be achieved.

    Patent expiration dates:

    • November 10, 2030
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
    Patent 8,450,344
    Issued: May 28, 2013
    Assignee(s): Aerie Pharmaceuticals, Inc.

    Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.

    Patent expiration dates:

    • July 11, 2026
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
    Patent 9,096,569
    Issued: August 4, 2015
    Assignee(s): Aerie Pharmaceuticals, Inc.

    Disclosed are beta and gamma-amino isoquinoline amide compounds and substituted benzamide compounds. In particular, the invention provides compounds that affect the function of kinases in a cell and that are useful as therapeutic agents or with therapeutic agents. The compounds of the invention are useful in the treatment of a variety of diseases and conditions including eye diseases such as glaucoma, cardiovascular diseases, and diseases characterized by abnormal growth, such as cancers. The invention further provides compositions containing the beta or gamma-amino isoquinoline amide compounds or substituted benzamide compounds.

    Patent expiration dates:

    • July 11, 2026
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Combination therapy
    Patent 9,415,043
    Issued: August 16, 2016
    Assignee(s): Aerie Pharmaceuticals, Inc.

    Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

    Patent expiration dates:

    • March 14, 2034
      ✓ 
      Drug substance
  • Combination therapy
    Patent 9,931,336
    Issued: April 3, 2018
    Assignee(s): Aerie Pharmaceuticals, Inc.

    Described herein are compounds and compositions for treating glaucoma and/or reducing intraocular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together form a salt.

    Patent expiration dates:

    • March 14, 2034
      ✓ 
      Patent use: REDUCTION OF ELEVATED INTRAOCULAR PRESSURE
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • December 18, 2022 - NEW CHEMICAL ENTITY

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.